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Background: Clopidogrel is a prodrug that is metabolised to its active metabolite by the hepatic cytochrome P450 system. Calcium channel 
blockers (CCB) are metabolised by the same pathway and may therefore attenuate the antiplatelet effect of clopidogrel. The aim of this study was to 
assess the impact of CCB therapy on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug eluting stent (DES) placement.
Methods: A total of 1,608 consecutive patients were previously enrolled in a study that aimed to assess the relation between platelet 
reactivity and outcomes after coronary stenting. Here, this cohort was analyzed according to concomitant CCB therapy at admission. The primary 
pharmacodynamic endpoint was platelet aggregation (in AU * min) with multiple electrode platelet aggregometry (MEA) after loading with 600mg 
clopidogrel. The primary clinical endpoint was death or definite stent thrombosis (ST) at 30 days. Secondary endpoints included definite ST alone, 
myocardial infarction (MI) and death.
Results: 232 patients (14.4%) were on CCBs on admission. Compared to patients with CCB medication, patients without CCB medication showed 
no significant difference in median [IQR] platelet aggregation values (232 [142;365] vs. 223 [141;368] AU * min, p=0.53). There was also no 
significant difference regarding the clinical endpoint in death or ST (2 [0.9%] vs.16 [1.2%], OR: 0.74; 95% CI: 0.17 to 3.2; p=0.69) between both 
groups.
Conclusions: In our population concomitant CCB therapy did not alter clopidogrel mediated platelet aggregation and did not have a measurable 
impact on stent thrombosis and mortality after coronary stenting.
